Mineralys Therapeutics, Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Mineralys Therapeutics is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $21.47, 54.6% below its 52-week high and below its 200-day average, which is falling.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. More about the company

$21.47

+2.04% today

$1.9B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is MLYS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S? 14w

S2 14w

S2 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 14w → S4 8w → S1 6w → S2 8w → S3 10w → S2 4w → S3 7w → S4 4w → S1 2w → S2 8w → S3 3w → S4 9w → S1 3w → S2 14w → S3 5w → S2 16w → S3 13w → S4 9w → S1 4w → S4 9w → S1 4w → S4 3w current

Total tracked: 164 weeks across 22 stage runs.

MLYS among Biotechnology358th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…358	MLYSMineralys Therapeutics, Inc.	Stage 4 · wk 3	23	−20.2%

vs 52W High

-54.6%

$20.30 lo$47.33 hi

54.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.6%

200 DMA: $27.38 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.65x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-20.2%

-19.6%

-24.6%

YTD

-39.9%

-50.5%

Scan Membership

Breakout Watch

Latest: 2025-04-16

4 appearances in last 60 days. First seen: 2024-03-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.65x

2026-10-21S4

Wk 3 · Vol 0.61x

2026-10-20S4

Wk 3 · Vol 0.79x

2026-10-19S4

Wk 3 · Vol 0.89x

2026-10-16S4

Wk 2 · Vol 0.95x

2026-10-15S4

Wk 2 · Vol 0.89x

2026-10-14S4

Wk 2 · Vol 0.95x

2026-10-13S4

Wk 2 · Vol 2.86x

2026-10-12S4

Wk 2 · Vol 0.86x

2026-10-09S4

Wk 1 · Vol 0.78x

2026-10-08S4

Wk 1 · Vol 2.00x

2026-10-07S4

Wk 1 · Vol 0.89x

Moving averages & range

50 DMA

$25.46

200 DMA

$27.38

52W High

$47.33

52W Low

$20.30

5D Low

$20.30

Resistance levels (recent highs)

20d High

$25.86

60d High

$31.12

120d High

$31.54

250d High

$47.33

Next resistance

+20.4%

to 20d High

ROE

-80.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.4

Mineralys Therapeutics: quick answers

What stage is Mineralys Therapeutics in?

As of Oct 22, 2026, Mineralys Therapeutics (MLYS) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean

Is Mineralys Therapeutics in an uptrend?

No. Mineralys Therapeutics is in a Stage 4 downtrend. It trades 21.6% below its 200-day average, which is falling.

How far is Mineralys Therapeutics from its 52-week high?

Mineralys Therapeutics closed at $21.47 on Oct 22, 2026, 54.6% below its 52-week high of $47.33. Its 52-week low is $20.30.

How has Mineralys Therapeutics performed over the past year?

As of Oct 22, 2026, Mineralys Therapeutics is down 50.5% over the past year and down 39.9% so far in 2026.

Which sector and industry is Mineralys Therapeutics in?

Mineralys Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.